FIELD: medicine, pharmaceutics.
SUBSTANCE: according to the invention, a pharmaceutical composition contains aripiprazole metabolite combined with serotonin reuptake inhibitor. Aripiprazole metabolite is chosen from dehyoaripiprazole DM-1458, DM-1451, DM-1452, DM-1454 or DCPP. Aripiprazole metabolite is a stabiliser of dopamine-serotonin system. Serotonin reuptake inhibitor can be fluoxetine, duloxetine, venlafaxine, milnaciprane, citalopram, fluvoxamine, paroxetin, sertraline or escitalopram and their salts. The pharmaceutical composition contains one weight part of said aripiprazole metabolite and 0.01 to 50 weight parts of said serotonin reuptake inhibitor. The pharmaceutical composition under the invention can be used for treating the patients with phrenopathies, particularly with depression or major depressive disorder.
EFFECT: pharmaceutical composition is effective and does not cause by-effects.
22 cl, 8 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR PHRENOPATHY TREATMENT | 2003 |
|
RU2356554C2 |
| DERIVATIVES OF CARBOSTYRIL AND STABILISERS OF MOOD FOR TREATMENT OF DISORDERS OF MOOD | 2004 |
|
RU2359675C2 |
| USING CANNABINOIDS COMBINED WITH ANTIPSYCHOTIC DRUG PREPARATION | 2008 |
|
RU2503448C2 |
| TREATING PSYCHOLOGICAL CONDITIONS WITH USING M-MUSCARINIC ANTAGONISTS | 2007 |
|
RU2477634C2 |
| METHOD OF TREATING MAJOR DEPRESSION IN HUMAN | 2007 |
|
RU2445973C2 |
| ORGANIC COMPOUNDS | 2017 |
|
RU2733975C2 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2785871C2 |
| THE SELECTIVE INVERSE AGONISTS OF SEROTONIN RECEPTORS AS MEDICATION TO CURE DISEASES | 2005 |
|
RU2442607C2 |
| CRYSTALLINE FORM OF 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUND | 2009 |
|
RU2503662C2 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2728787C2 |
